Azaindazole compounds as CCR1 receptor antagonists
US8163918B2 · kind B2 · utility
0Cited by
31References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2011 |
| Grant date | Apr 24, 2012 |
| Priority date | — |
| Expiry date | Oct 14, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are intermediates thereof, and methods of making and methods of using same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.